Lawrence R. Nycum - Concepedia

Author

Lawrence R. Nycum

Also Known As

D. Boulware, L. Nycum, L. R. Nycum, L.R. Nycum, LAWRENCE R. NYCUM, Lawrence Nycum, Lawrence R Nycum, Lawrence R. Nycum, Patefield, A J

Publications

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Regional Cancer Center David Grant USAF Medical Center University of Washington New York University

About

Lawrence R. Nycum is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	551
2	Public Health	2	2	75
3	Health Sciences	1	1	35
4	Cell Biology	1	1	19
5	Gastroenterology	1	1	22

Lawrence R. Nycum

Publications

Citations

H-Index

Page 1

	Year	Citations
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff, Journal of Clinical Oncology	2012	1.4K
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer Carol Aghajanian, Barbara A. Goff, Lawrence R. Nycum, Gynecologic Oncology MedicineCancer ManagementGynecologySafety AnalysisFinal Overall Survival	2015	306
Age-Specific Survival of Women with Endometrioid Adenocarcinoma of the Uterus John Farley, Lawrence R. Nycum, Michael J. Birrer, Gynecologic Oncology Uterine FibroidsGynecological SurgeryGynecologyAge-specific SurvivalPublic Health	2000	45
OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). C. Aghajanian, N. Finkler, T. Rutherford, Journal of Clinical Oncology ImmunologyGynecologyPlatinum-sensitive RecurrentImmunotherapyGynecology Oncology	2011	35
Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancer☆☆The views expressed herein are those of the authors and do not reflect the official opinion of the Department of Defense or the United States Army or Air Force. Edward R. Kost, Kevin L. Hall, Jeffrey F. Hines, Gynecologic Oncology Air ForceCancer RiskCancer EpidemiologyAsian-pacific Islander RacePoor Outcome	2003	30
The Role of p27 in Endometrial Carcinoma Lawrence R. Nycum, L.M. Smith, John Farley, Gynecologic Oncology Tumor BiologyGynecologyEndometrial CarcinomaMedicineCancer Research	2001	29
Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer Carol Aghajanian, Barbara A. Goff, Lawrence R. Nycum, Gynecologic Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2014	24
Asymptomatic Intussusception of the Appendix Due to Endometriosis Lawrence R. Nycum, Heather E. Moss, JOHN Q. ADAMS, Southern Medical Journal Gynecological SurgeryEndometriosisGastroenterologyGynecologyRare Nature	1999	22
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum‐sensitive ovarian cancer Angeles Alvarez Secord, Andrew Berchuck, Robert V. Higgins, Cancer	2011	19
Endocervical Cancer Is Associated with an Increase in the Ligands and Receptors for Transforming Growth Factor-β and a Contrasting Decrease in p27Kip1 John Farley, Karen Gray, Lawrence R. Nycum, Gynecologic Oncology Growth Factor-βTumoral PathologyMedicinePathologyCancer Cell Biology	2000	19

Page 1